SAN CARLOS, Calif.--(BUSINESS WIRE)--POINT Biomedical Corp. announced today that Thomas L. Feldman has joined POINT as President, Chief Executive Officer, and Member of the Board of Directors. "We are delighted that Tom has joined POINT. Tom is well qualified to lead POINT through FDA approval and commercialization of our lead product, CARDIOsphere®, as well as development of our other exciting pipeline products," said Jon Saxe, Chairman of the Board of Directors.
"I was attracted to POINT's near-term market opportunity to commercialize CARDIOsphere," said Tom Feldman. Mr. Feldman continued, "CARDIOsphere is designed to enable cardiologists to perform a low-cost, patient-friendly, non-radioactive office procedure to detect coronary artery blood flow. We believe, once approved, cardiologists will be eager to use CARDIOsphere because of its expected advantages to patients over current technologies."
Mr. Feldman has over 30 years of pharmaceutical industry experience. Prior to joining POINT, Mr. Feldman was President and Chief Business Officer at COTHERIX, Inc. from 2004-2006. He was instrumental in launching that company's first product, completing its initial public offering, and negotiating the acquisition of the company by Actelion earlier this year. From 1995-2002 he was Vice President of Sales and Marketing at Scios, Inc. where he directed the successful launch of a new cardiovascular drug that led to the acquisition of Scios by Johnson & Johnson in 2002 for $2.4 billion. Mr. Feldman started his career in sales and marketing with Johnson and Johnson in 1973 and held numerous senior management positions at McNeil Pharmaceutical and Ortho Pharmaceutical. He is a graduate of North Dakota State University.
About POINT Biomedical:
POINT Biomedical is developing novel technology platforms for imaging applications. The lead product, CARDIOsphere, is an ultrasound-imaging agent for assessing myocardial perfusion. It is currently in advanced clinical testing in the United States. Depending upon the outcome of the Phase 3 trials, CARDIOsphere could allow a cardiologist to determine the state of a patient's coronary artery circulation in the office setting, without the use of radioactive isotopes.
The matters discussed in this press release are forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. The receipt of regulatory approvals, results of product development programs, and clinical efficacy of and market demand for products, among other matters, may differ significantly from the discussion of such matters in the forward-looking statements.
CONTACT INFORMATION: POINT Biomedical Corporation, 887L Industrial Road, San Carlos, CA 94070, (650) 596-1400 phone; (650) 596-1402 fax. For inquires please contact Malcolm Farnsworth, CFO, mfarnsworth@POINTbio.com, or visit our website at www.POINTbio.com
Contact:
POINT Biomedical Corporation
Malcolm Farnsworth, CFO, 650-596-1400
fax: 650-596-1402
mfarnsworth@POINTbio.com
www.POINTbio.com
Source: POINT Biomedical Corporation
>>> Discuss This Story